The Onkologia Story
Evestra Onkologia Sp. z o.o is a Polish biopharmaceutical start-up company located in Lodz launched by a distinguished team with an impressive record in developing and commercializing innovative oncology and other proliferative diseases products.
The Company was launched as a wholly-owned subsidiary of Evestra, Inc., a U.S.A. biopharmaceutical company based in San Antonio, Texas. The key mission of Evestra Onkologia is to develop highly innovative oncology and antiproliferative assets such as endometriosis and fibroids in Poland, and the EU. To accomplish its core mission, the Company has and will continue to establish a variety of fruitful collaborations with leading Polish research institutions and investigators and for-profit CRO companies in Poland, to enhance development and commercialization of its innovative assets. Evestra Onkologia managing board is led by two executives of the pharmaceutical as well as life science industry with extensive in drug development and managing companies with multinational divisions. Dr. Ze’ev Shaked, Ph.D. has multi-disciplinary track record in oncology including development and commercialization of novel antimetabolites to treat hematological cancers, biologics such as cytotoxic monoclonal antibodies and cytokines to treat a wide range of solid tumor indications. Both board members hold numerous patents and have managed R&D departments and projects for many years. Dr Maciej Wierzbicki, Ph.D. has experienced the development of early stage ventures in the field of life science technology, including the acquisition of financing and project management
Evestra Onkologia is proud to obtain funding from the Operational Programme Smart Development for the project entitled “Development of selective treatment of endometriosis based on mesoprogestins”.
The aim of this project is to develop a novel and only- in- class, mesoprogestin – EC313 to treat endometriosis. Although EC313 can be described as a SPRMs, it significantly differs from other representatives of this class. EC313 has been characterized as a mesoprogestin, chemistry compound in which the agonistic and antagonistic activity ratio has been optimized. This project is the business foundation of Evestra Oncology in Poland and serves as the basis for the long-term development of the Evestra Onkologia as a biopharmaceutical company.
The project is co-financed by the European Union from the European Regional Development Fund and the state budget. Total project budget: 18, 706, 957.80 zł.